Q-omics provides the consensus-scored KRTAP5-6 profile across patient tissues and cancer cell-line models. KRTAP5-6 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, KRTAP5-6 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, KRTAP5-6 RNA expression shows 7,641 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, LIHC, and TGCT as cancer lineages where KRTAP5-6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTAP5-6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTAP5-6 survival associations across molecular data types. KRTAP5-6 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTAP5-6 RNA expression–survival associations across cancer types. High KRTAP5-6 expression shows unfavorable associations in PCPG, SKCM, STAD, CHOL and KIRC, but favorable associations in BRCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .010). Together, the overview and detailed table identify BRCA as the clearest survival context for KRTAP5-6 RNA expression.
This table summarizes KRTAP5-6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRTAP5-6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTAP5-6 shows lower tumor expression in THCA and higher tumor expression in LIHC, BRCA, LUSC, HNSC and STAD. The LIHC box plot shows higher KRTAP5-6 RNA expression in tumor versus normal tissue (log2 FC = +0.968, t-test p < 0.001).
This table shows molecular features associated with KRTAP5-6 in patient tissues and cancer cell lines. In patient samples, KRTAP5-6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KRTAP5-6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
